AIM ImmunoTech Inc 8-K, filed Apr 19, 2021
AIM ImmunoTech Inc. (AIM)
About this 8-K
AIM ImmunoTech Inc filed this 8-K on April 19, 2021.
Items reported
- Item 1.01: Entered into a material agreement
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM8-K
CURRENTREPORT
Pursuantto Section 13 or 15(d) of the
SecuritiesExchange Act of 1934
Date of Report (Date of earliest event reported)
April19, 2021
AIMIMMUNOTECH INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001 - 27072 | 52-0845822 |
|---|---|---|
| (state<br> or other jurisdiction | (Commission | (I.R.S.<br> Employer |
| of<br> incorporation) | File<br> Number) | Identification<br> No.) |
| 2117 SW Highway 484, Ocala FL | 34473 | |
| --- | --- | |
| (Address<br> of principal executive offices) | (Zip<br> Code) |
Registrant’s telephone number, including area code: (352) 448-7797
AIM ImmunoTech Inc.
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| [ ] | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities registered pursuant to Section 12(b) of the Act:
| Title<br> of each class | Trading<br> Symbol | Name<br> of each exchange on which registered |
|---|---|---|
| Common<br> Stock, par value $0.001 per share | AIM | NYSE<br> American |
Item1.01 Entry into a Material Definitive Agreement.
On April 14, 2021, we entered into a material transfer and research agreement with Roswell Park Comprehensive Cancer Center pursuant to which Roswell Park will conduct pre-clinical testing using cell culture and animal models testing Ampligen in various tumor types.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AIM<br> IMMUNOTECH INC. | ||
|---|---|---|
| April<br> 19, 2021 | By: | /s/ Thomas K. Equels |
| Thomas<br> K. Equels, CEO |